Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Shares notification

31 Jan 2007 09:37

ReNeuron Group plc31 January 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer RENEURON GROUP PLCof existing shares to which voting rights are attached 2. Reason for the notification (please tick the appropriate box or boxes)An acquisition or disposal of voting rights X An acquisition or disposal of financial instruments which may result in theacquisition of shares already issued to which rioting rights are attached An event changing the breakdown of voting rights 3. Full name of person(s) subject to the SAAD INVESTMENTS COMPANY LIMITED notification obligation4. Full name of shareholder(s) (if different from 3.) Vidacos Nominees Ltd (Citigroup Global AWAL)5. Date of the transaction and date on which the Not specified. threshold is crossed or reached6. Date on which issuer notified 30 January 2007 A: Voting rights attached to sharesClass/type Situation Resulting situation after the triggering transaction vi of shares previous to the Triggering if possible transactionusing the ISIN Number of Number Number of Number of voting rights % of voting rightsCODE Shares shares ix of Voting Rights Direct Direct Indirect Direct Indirect Ordinary Shares Not Not 18,950,000 18,950,000 0 15.988% 0 specified specified B: Financial InstrumentsResulting situation after the triggering transactionType of financial Expiration Exercise/Conversion Number of voting rights % of voting date Period/Date that may be acquired if rightsinstrument the instrument is - exercised/converted N/A - - - - Total (A+B)Number of voting rights % of voting rights 18,950,000 15.988% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectivelyheld, if applicable None specified. Proxy Voting: 10. Name of the proxy holder: N/A 11. Number of voting rights proxy holder will cease to hold: N/A12. Date on which proxy holder will cease to hold voting N/Arights: 13. Additional information: Recent acquisition. 14. Contact name: Michael Hunt, CEO15. Contact telephone number: 01483 302560 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Oct 201010:26 amRNS18th Annual BioPartnering Europe conference
8th Sep 201011:07 amRNSResults of 2010 Annual General Meeting
8th Sep 20107:00 amRNS2010 AGM Trading Update
9th Aug 20107:00 amRNSPosting of Report and Accounts and AGM date
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding
15th Jul 20107:00 amRNSNotification of Investor Evening
12th Jul 20107:00 amRNSResult of pre-clinical studies
29th Jun 20107:00 amRNSPreliminary Results
17th Jun 20107:00 amRNSPreliminary Results Notification
13th May 20102:38 pmRNSBlock listing application
29th Apr 20107:00 amRNSNew positive data to be presented at US conference
1st Apr 20109:58 amRNSHolding in Company
31st Mar 20104:35 pmRNSHolding(s) in Company
22nd Mar 201010:44 amRNSReNeuron cited as UK regenerative medicine leader
18th Mar 20107:00 amRNSReNeuron signs further manufacturing contracts
15th Mar 20102:44 pmRNSSecond Closing of the Placing
12th Mar 201012:18 pmRNSResult of General Meeting
3rd Mar 20107:00 amRNSReNeuron presents pre-clinical efficacy data
22nd Feb 20107:00 amRNSReNeuron Announces Fundraising
18th Feb 20107:00 amRNSRetinal Stem Cell Research Grant
10th Feb 20107:00 amRNSFinal Approval Received To Commence Stroke Trial
8th Feb 201012:55 pmRNSIssue of Ordinary Shares
1st Feb 20107:00 amRNSClinical Advisory Board appointments
28th Jan 20107:00 amRNSRegulatory update
27th Jan 201011:42 amRNSReNeuron welcomes "Life Sciences 2010" report
1st Dec 20097:00 amRNSIssue of Ordinary Shares
27th Nov 20097:00 amRNSTwo grants awarded by regenerative funding program
26th Nov 20097:02 amRNS?5 million equity funding facility secured
26th Nov 20097:00 amRNSHalf Yearly Report
23rd Nov 20097:00 amRNSNotice of Results
16th Nov 20097:00 amRNSPositive data presented at leading US conference
22nd Oct 20091:49 pmRNSReNeuron to present at Royal Society of Medicine
2nd Oct 20097:00 amRNSPublication of new research using ReNcell
17th Sep 200910:47 amRNSResult of AGM
17th Sep 20097:00 amRNSAGM Statement
14th Sep 20097:02 amRNSTrading Platform
14th Sep 20097:00 amRNSChange of Adviser
10th Sep 20097:00 amRNSAngel and Reneuron announce contract
10th Sep 20097:00 amRNSRe Agreement
9th Sep 20095:00 pmRNSHolding(s) in Company
12th Aug 20097:00 amRNSDirector/PDMR Shareholding
11th Aug 20097:00 amRNSPublication of papers in peer-reviewed journals
10th Aug 20099:28 amRNSPublication of pre-clinical data
31st Jul 200911:21 amRNS2008/09 Annual Report and Accounts
30th Jul 200910:05 amRNSRegulatory Update
14th Jul 20093:48 pmRNSLaunch of "Life Sciences Blueprint"
8th Jul 20099:33 amRNSPublication of data on lead CTX stem cell line
30th Jun 20097:00 amRNSFinal Results
29th Jun 20093:44 pmRNSHolding(s) in Company
24th Jun 200910:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.